Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Veterinary Renal Disease Market

Veterinary Renal Disease Market Trends

Report ID: GMI8426
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Veterinary Renal Disease Market Trends

Increasing pet ownership trend has led to a greater demand for veterinary services and products aimed at addressing the health needs of pets, including the diagnosis, treatment, and management of renal disease. This trend is expected to continue driving growth in the market.
Moreover, pet owners are increasingly willing to invest in diagnostic testing to ensure the early detection and management of health conditions in their pets. This includes routine bloodwork, urinalysis, and imaging studies such as ultrasound, which can aid in the early diagnosis of renal disease among pets. Thus, the growing demand for diagnostic testing fuels the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Veterinary renal disease market size was USD 15.9 billion in 2023 and is expected to register 5.9% CAGR from 2024-2032 owing to the rise in pet ownership and advances in animal diagnostics worldwide.

The treatment segment held 67.3% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to the growing prevalence of kidney disorders in animals, that increases the demand for effective treatment options.

North America veterinary renal disease industry reached USD 7 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the increasing emphasis on comprehensive animal healthcare in the region.

Dechra Pharmaceuticals, Elanco Animal Health Incorporated, General Mills Inc., Hill's Pet Nutrition, Inc., IDEXX Laboratories, Inc., The J.M. Smucker Company, Mars Incorporated, Merck & Co., Inc., and Nestle Purina, are some of the major veterinary renal disease companies worldwide.